menu
    • menu

    Company profile for Biomunex Pharmaceutical

    NEW Drugs in Dev: 2
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    BIOMUNEX is a French biopharmaceutical company, founded in 2014 in Paris, focused on the discovery and development of innovative bispecific antibody therapeutics, based on a proprietary platform, to address unmet medical needs. Based on its unique proprietary platform, BIOMUNEX is developing cutting-edge immunotherapies for several cancer types. Its ‘Plug and Play’ modular bispecific antibody BiXAb platform enables BIOMUNE...
    BIOMUNEX is a French biopharmaceutical company, founded in 2014 in Paris, focused on the discovery and development of innovative bispecific antibody therapeutics, based on a proprietary platform, to address unmet medical needs. Based on its unique proprietary platform, BIOMUNEX is developing cutting-edge immunotherapies for several cancer types. Its ‘Plug and Play’ modular bispecific antibody BiXAb platform enables BIOMUNEX to develop drug candidates with high anti-tumor potential, superior manufacturability and optimal drug-like properties.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Biomunex PharmaceuticalFrance Flag
    Country
    Country
    France
    Address
    Address
    14 avenue d’Eylau 75116 PARIS
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.biomunex.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/biomunex-pharmaceuticals
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/hashtag/biomunex?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biomunex To Showcase MAIT Engager Platform Data
    Biomunex To Showcase MAIT Engager Platform Data

    07 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251107376297/en/Biomunex-to-Present-Preclinical-Data-of-its-MAIT-Engager-Platform-in-Immuno-Oncology-at-2025-SITC-Annual-Meeting

    BUSINESSWIRE
    07 Nov 2025
    Share Share
    Biomunex Secures Investment To Advance Cancer Immunotherapy
    Biomunex Secures Investment To Advance Cancer Immunotherapy

    30 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-30/biomunex-announces-investment-from-new-shareholders-to-accelerate-its-growth-and-development-of-its-portfolio-of-innovative-bispecific-antibodies-for

    PHARMAWEB
    30 Sep 2025
    Share Share
    Ipsen doubles up in TCEs for cancer, adding Biomunex drug
    Ipsen doubles up in TCEs for cancer, adding Biomunex drug

    04 Dec 2024

    // PHARMAPHORUM

    https://pharmaphorum.com/news/ipsen-doubles-tces-cancer-adding-biomunex-drug

    PHARMAPHORUM
    04 Dec 2024
    Share Share
    Biomunex Signs Exclusive Licensing Agreement With Institut Curie
    Biomunex Signs Exclusive Licensing Agreement With Institut Curie

    04 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240304329096/en

    BUSINESSWIRE
    04 Mar 2024
    Share Share
    Biomunex Announces the Start of Phase 1 for First-in-class Bispecific Antibody
    Biomunex Announces the Start of Phase 1 for First-in-class Bispecific Antibody

    24 Jan 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240124510203/en

    BUSINESSWIRE
    24 Jan 2024
    Share Share
    Biomunex Presents Results on Disruptive MAIT Cell Redirection Approach
    Biomunex Presents Results on Disruptive MAIT Cell Redirection Approach

    12 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230412005478/en

    BUSINESSWIRE
    12 Apr 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search